Company news

Century Therapeutics, Inc. (NASDAQ:IPSC) news

Century Therapeutics, Inc. news releases on 6ix. Latest, Oct 2, 2026: Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via…

Century Therapeutics, Inc. (NASDAQ:IPSC) news

Press releases & updates

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

IHI Power Services Corp. Rebrands as Kyuden Energy Partners Following Acquisition by Japan's Kyuden Group

Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026

New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026

Century Therapeutics Reports First Quarter Financial Results and Business Updates

Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions

Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates

Century Therapeutics to Participate in Upcoming Investor Conferences in March

Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes

Century Therapeutics : Initial Statement of Beneficial Ownership (Form 3)

Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors

Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting

Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference

Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer

Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting

Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer

Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases

Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition